Rapid Micro Biosystems, Inc. posted strong FY25 revenue growth, driven by Growth Direct system placements, but remains unprofitable with a $47M net loss. RPID's growth hinges on large multi-system ...
Robert Spignesi, CEO, opened by highlighting third quarter revenue of $7.8 million, which was above the midpoint of guidance and marked the twelfth consecutive quarter meeting or beating revenue ...
LEXINGTON, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation ...
Reports record fourth quarter 2025 total revenue of $11.3 million, representing 37% growth compared to fourth quarter 2024 Amgen expands global Growth Direct system rollout with significant ...
Rapid Micro Biosystems and Merck KGaA have signed a five-year global distribution agreement for Growth Direct systems and consumables. Rapid Micro Biosystems, Inc. has entered a five-year global ...
The new Rapid Sterility application includes a novel, proprietary test kit that has been developed for use with the Company’s fully automated Growth Direct system and delivers time to organism ...